Ardent Health (NYSE:ARDT) Shares Gap Down After Earnings Miss

Key Points

• Q4 EPS miss: Ardent reported $0.32 EPS vs. a $0.35 consensus and $1.61B revenue vs. $1.63B expected, and the stock gapped down to open at $8.62 on the news.
• Guidance disappointment: Management set FY2026 EPS guidance of $0.90–$1.27—well below the ~1.40 consensus—triggering analyst price‑target cuts and rating downgrades.
• Accounting and legal risk: Allegations of aggressive receivables practices, a reported ~$97M "180‑day cliff" accounting shock, and ensuing investigations and class actions raise the risk of restatements, charges, and litigation costs.

Ardent Health, Inc. (NYSE:ARDT - Get Free Report) gapped down before the market opened on Thursday after the company announced weaker than expected quarterly earnings. The stock had previously closed at $9.64, but opened at $8.62. Ardent Health shares last traded at $9.41, with a volume of 323,257 shares trading hands.

The company reported $0.32 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.35 by ($0.03). Ardent Health had a net margin of 3.24% and a return on equity of 19.02%. The firm had revenue of $1.61 billion during the quarter, compared to analyst estimates of $1.63 billion. Ardent Health has set its FY 2026 guidance at 0.900-1.270 EPS.

Ardent Health News Roundup

Here are the key news stories impacting Ardent Health this week:

• Neutral Sentiment: Company published Q4 results, slides and hosted a conference call where details of the quarter and guidance were discussed. Q4 press release & slides
• Negative Sentiment: Q4 results missed estimates: EPS $0.32 vs. consensus ~$0.35 and revenue $1.61B vs. ~$1.63B; management issued FY‑2026 EPS guidance of $0.90–$1.27 (well below the ~1.40 consensus) and revenue guidance toward the low end of expectations — a clear near‑term earnings and guidance disappointment. Zacks: Q4 miss
• Negative Sentiment: Allegations and investor suits focus on receivables/collectability practices (an alleged “180‑day cliff” reserve policy and a reported ~$97M accounting shock), prompting investigations and raising concerns about past disclosures and reserve adequacy. That heightens earnings uncertainty and potential restatement/charge risk. Hagens Berman investigation
• Negative Sentiment: Multiple law firms have filed or are soliciting lead‑plaintiff applications in securities class actions alleging undisclosed collections problems and related misstatements; one filing cites a ~33% stock decline tied to these issues. Ongoing litigation increases settlement/legal‑cost risk and generally pressures sentiment and liquidity. BFA Law class action notice

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on ARDT shares. Morgan Stanley reiterated an "equal weight" rating and issued a $12.00 price objective (down from $22.00) on shares of Ardent Health in a research report on Friday, November 14th. KeyCorp cut shares of Ardent Health from an "overweight" rating to a "sector weight" rating in a report on Monday, November 17th. Guggenheim lowered their price objective on shares of Ardent Health from $18.00 to $15.00 and set a "buy" rating for the company in a research report on Tuesday, November 18th. Wall Street Zen cut shares of Ardent Health from a "buy" rating to a "hold" rating in a research report on Sunday, November 23rd. Finally, UBS Group dropped their price target on Ardent Health from $14.50 to $14.00 and set a "buy" rating on the stock in a research note on Thursday, December 18th. Six equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, Ardent Health has an average rating of "Hold" and a consensus price target of $14.58.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd grew its stake in shares of Ardent Health by 2,036.6% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 4,786 shares of the company's stock valued at $42,000 after buying an additional 4,562 shares in the last quarter. Alpine Global Management LLC acquired a new stake in Ardent Health in the fourth quarter valued at $172,000. Monetary Solutions Ltd acquired a new stake in Ardent Health in the fourth quarter valued at $79,000. Invesco Ltd. grew its position in shares of Ardent Health by 24.4% in the 4th quarter. Invesco Ltd. now owns 71,304 shares of the company's stock valued at $630,000 after acquiring an additional 13,964 shares during the period. Finally, Empowered Funds LLC increased its stake in shares of Ardent Health by 135.0% during the 4th quarter. Empowered Funds LLC now owns 551,738 shares of the company's stock worth $4,872,000 after purchasing an additional 316,961 shares during the last quarter.

Ardent Health Stock Performance

The company has a market capitalization of $1.36 billion, a P/E ratio of 6.53, a PEG ratio of 5.18 and a beta of 0.46. The stock's fifty day moving average price is $9.00 and its 200-day moving average price is $11.04. The company has a debt-to-equity ratio of 0.67, a quick ratio of 1.95 and a current ratio of 2.08.

Ardent Health Company Profile

Ardent Health, listed on the New York Stock Exchange under the ticker ARDT, is a healthcare delivery company focused on acquiring, developing and managing acute care hospitals and complementary outpatient facilities across the United States. The company's integrated platform encompasses both inpatient and outpatient services, designed to provide end-to-end care solutions and address the full continuum of patient needs.

Through its network, Ardent Health operates general hospitals, emergency departments, ambulatory surgery centers, urgent care clinics, rehabilitation and post-acute care facilities.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.